Sanofi (SNY) Common Equity (2009 - 2026)

Sanofi has disclosed Common Equity across 18 years of filings, most recently posting $80.9 billion for Q2 2026.

• In Q2 2026, Common Equity rose 1.65% year-over-year to $80.9 billion; the TTM figure through Jun 2026 stood at $80.9 billion (up 1.65% YoY), while the FY2025 annual figure was $83.5 billion, down 0.94% from the prior year.
• Common Equity came in at $80.9 billion for Q2 2026 at Sanofi, down from $83.5 billion in the prior quarter.
• In the past five years, Common Equity ranged from a high of $83.5 billion in Q4 2025 to a low of $76.1 billion in Q2 2022.
• Average Common Equity over 5 years is $79.8 billion, with a median of $79.6 billion recorded in 2025.
• Year-over-year, Common Equity declined 2.91% in 2022 and climbed 4.4% in 2023.
• Over 5 years, Common Equity stood at $76.7 billion in 2022, then increased by 4.34% to $80.0 billion in 2023, then gained by 4.0% to $83.2 billion in 2024, then grew by 0.33% to $83.5 billion in 2025, then declined by 3.13% to $80.9 billion in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $80.9 billion in Q2 2026, $83.5 billion in Q4 2025, and $79.6 billion in Q2 2025.